Preliminary efficacy and safety results of glufosfamide (GLU) in relapsed soft tissue sarcoma: Results of a phase II trial
| Autor: | Claire F. Verschraegen, Douglas Adkins, Stew Kroll, Kristen N. Ganjoo, Lee D. Cranmer, D. S. Mendelson, Virginia K. Langmuir, Glenn D. Rosen, G. Z. D'Amato |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Leiomyosarcoma
Cancer Research medicine.medical_specialty Ifosfamide business.industry Soft tissue sarcoma Glufosfamide Urology Phases of clinical research Histology medicine.disease Surgery chemistry.chemical_compound Oncology chemistry Clinical endpoint Medicine Angiosarcoma business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 26:10591-10591 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2008.26.15_suppl.10591 |
| Popis: | 10591 Background: Glufosfamide is glucose linked to isophosphoramide mustard, the active metabolite of ifosfamide. Ifosfamide is known to have activity in soft tissue sarcoma. The objectives of this study are to evaluate the safety and efficacy of GLU in patients (pts) with soft tissue sarcoma. Methods: This 1-stage phase 2 study planned to enroll 22 pts with metastatic and/or advanced unresectable soft tissue sarcoma previously treated with 1–2 prior systemic therapies. Prior ifosfamide was allowed unless most recent relapse occurred within 4 weeks of completion of ifosfamide. Pts received GLU 5000 mg/m2 IV over 1 hour every 21 days for up to 6 cycles. Primary endpoint was confirmed response rate. FDG PET scans were collected prior to Cycle 3 if PET positive at baseline. Results: 11 male/11 female pts enrolled; 2 did not meet all eligibility criteria. Median age 52 y (range: 19–77); ECOG 0/1 (16) and 2 (6). Histology: leiomyosarcoma (8), synovial (5), angiosarcoma (3), other (6). Four pts completed 6 cyc... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|